CClinicalTrials.gg
RecruitingNCT06366048RNLVUpdated Apr 14, 2026

A Study on Relationship Between Resected Normal Liver Parenchymal Volume(RNLV)and Post-Hepatectomy Liver Failure (PHLF)

An observational study in Liver Failure, sponsored by National Natural Science Foundation of China. Recruiting at 3 sites in China. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by National Natural Science Foundation of China · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,600
Sex
All
01

Study summary

The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.

Read the detailed description

The investigator launched a large sample-size and retrospective study, enrolling more than a thousand consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma (ICC) underwent hepatotectomy from the investigator's center. The primary aim of study was to identify whether there was strong correlation between RNLV and PHLF, and the second aim was to further build a combination model based on RNLV and evaluate the value of predicting PHLF in clinical practice. The investigators attached same importance to RNLV, compared to future liver remnant, especially for patients with massive tumors and multiple tumors. The investigators hyperthesized that RNLV could be an indicative variable for surgical safety, and help to form a diversifying method to comprehensively assess the risk of PHLF preoperatively.

02

Conditions studied

  • Liver Failure

Browse trials for

Keywords

  • resected normal parenchymal volume (RNLV)
  • postoperative hepatectomy liver failure (PHLF)
  • future liver remnant (FLR)
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

1133 consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma underwent hepatectomies.

Inclusion criteria

  • selective hepatectomies;
  • histologically confirmed as HCC and ICC
  • complete and accessible data

Exclusion criteria

Exclusion criteria:

  • any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
  • any history of portal vein embolism (PVE)
  • any history of tumor rupture
  • emergency surgery
  • pathologically diagnosed with neither HCC nor ICC
  • concomitant resection of gastrointestinal organs, spleenectomy or other organs
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,600 participants (estimated)
Patient registry
No

Groups and cohorts

  • PHLF group

    One group was defined as post-operative liver failure accroding to the PHLF definition of 50-50 criteria and ISGLS criteria.

    Diagnostic Test: the different definitions of PHLF according to 50-50 criteria and ISGLS criteria

  • No PHLF group

    One group was defined as no post-operative liver failure accroding to the PHLF definition of 50-50 criteria nor ISGLS criteria.

Interventions

  • Diagnostic testthe different definitions of PHLF according to 50-50 criteria and ISGLS criteria

    Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.

05

What researchers measure

Primary outcomes

  1. Probability of PHLF was predicted with our individual model based on RNLV.

    In our center, an increase international normalized ratio greater than 1.15 and concomitant hyperbilirubinemia more than 23μmol/L on or after postoperative day 5 would be defined as PHLF, according to the International Study Group of Liver Surgery.

    Time frame: postoperative day 1 to day 30.

06

Study locations

3 of 3 sites recruiting
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fujian, Shanghai Municipality, China
    Recruiting
  • The Third Affiliated Hospital of Naval Medical University
    Shanhai, Shanghai Municipality 201800, China
    Recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University
    Shenzhencun, Shanghai Municipality, China
    Recruiting
07

References and documents

Publications

  • Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol. 2019 Sep;71(3):523-533. doi: 10.1016/j.jhep.2019.05.008. Epub 2019 May 28. PubMed 31145929 ↗
  • Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463. doi: 10.21037/hbsn-20-480. PubMed 32832496 ↗
  • Renner P, Schuhbaum J, Kroemer A, Zeman F, Loss M, Lang SA, Geissler EK, Schlitt HJ, Farkas SA. Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg. 2016 Feb;401(1):43-53. doi: 10.1007/s00423-015-1359-y. Epub 2015 Dec 1. PubMed 26627084 ↗
  • Xie QS, Chen ZX, Zhao YJ, Gu H, Geng XP, Liu FB. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis. Asian J Surg. 2021 Jan;44(1):36-45. doi: 10.1016/j.asjsur.2020.08.019. Epub 2020 Sep 28. PubMed 32988708 ↗

Individual participant data

Plan to share: Yes — After we published our study paper, we would like to share IPD attached to our paper as website links.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT06366048
Lead sponsor
National Natural Science Foundation of China
Responsible party
Yuan-Yuan Wang (a clinical resident of general surgery department, National Natural Science Foundation of China) — Principal investigator
First posted
Apr 15, 2024
Start date
Dec 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 14, 2026

Study contacts

Yuan-yuan Wang
Contact
wangyuanyuan702@foxmail.com
+8615800332525
Gang Huang
Contact
squaror@163.com
+8613918663457
Yuan-yuan Wang
study director · Eastern Hepatobiliary Surgery Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion